Key Developments: Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

94.10USD
26 Dec 2014
Price Change (% chg)

$0.19 (+0.20%)
Prev Close
$93.91
Open
$94.23
Day's High
$94.33
Day's Low
$93.82
Volume
114,328
Avg. Vol
296,082
52-wk High
$96.97
52-wk Low
$77.92

Search Stocks

Latest Key Developments (Source: Significant Developments)

Novartis AG says Alcon's Travatan receives EU approval
Tuesday, 23 Dec 2014 01:15am EST 

Novartis AG:Says European Commission has approved additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma.Alcon says Travatan eye drops solution had been approved to reduce elevated intraocular pressure in pediatric patients.  Full Article

FDA approves Novartis AG's Xtoro to treat swimmer’s ear - Reuters
Tuesday, 16 Dec 2014 07:00pm EST 

Novartis AG:FDA approves Novartis' Xtoro to treat swimmer's ear - Reuters.FDA says Xtoro is an eardrop to treat acute otitis externa, commonly known as swimmer's ear.  Full Article

Novartis AG gains FDA approval for Signifor LAR to treat patients with acromegaly
Monday, 15 Dec 2014 07:00pm EST 

Novartis AG:Announces that FDA has approved Signifor long-acting release (LAR)* (pasireotide) for injectable suspension, for intramuscular use, for treatment of patients with acromegaly who have had inadequate response to surgery and/or for whom surgery is not option.  Full Article

Novartis Gilenya fails in study for a type of multiple sclerosis
Monday, 1 Dec 2014 01:18am EST 

Novartis AG:Drug Gilenya (fingolimod) failed to meet its main goal in a Phase III study as a treatment for primary progressive multiple sclerosis (PPMS).  Full Article

Novartis AG says heart failure drug wins faster review in Europe
Friday, 28 Nov 2014 01:15am EST 

Novartis AG:Says new heart failure drug LCZ696 was granted a speedier evaluation by European health regulator, shortening review by 60 days.  Full Article

Novartis AG presents phase III results showing AIN457 (secukinumab) significant efficacy in psoriatic arthritis patients
Sunday, 16 Nov 2014 02:30pm EST 

Novartis AG:Says presents phase III results showing AIN457 (secukinumab) significant efficacy in psoriatic arthritis patients.  Full Article

Novartis AG presents phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Saturday, 15 Nov 2014 04:45pm EST 

Novartis AG:Says presents phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients.  Full Article

Cipla Ltd asks government to revoke Novartis patents on respiratory drug - Reuters
Wednesday, 29 Oct 2014 08:00pm EDT 

Cipla Ltd:Says it had requested the Indian government to revoke five patents held by Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market - Reuters.Alleged that Novartis has had patents on the drug since 2008/09, but did not make it in India, and instead imported a negligible quantity from Switzerland, leading to a shortage of supply.Says it has potential to manufacture adequate quantities of the drug and make the same available in the country.  Full Article

Novartis AG reconfirms FY 2014 outlook
Tuesday, 28 Oct 2014 02:00am EDT 

Novartis AG:Confirms outlook for full FY 2014.Says group net sales in FY 2014 are expected to grow at low to mid-single digit rate.Says group core operating income is expected to grow ahead of sales in FY 2014, at mid to high-single digit rate.FY 2013 net sales of $57.9 billion.FY 2013 core operating income of $14.5 billion.  Full Article

Novartis AG announces divestiture of influenza vaccines business to CSL Ltd for $275 million
Sunday, 26 Oct 2014 05:01pm EDT 

Novartis AG:Enters into definitive agreement to divest its influenza vaccines business to CSL Ltd for agreed price of $275 million.Says this transaction requires regulatory approvals and is expected to close in second half of 2015.Novartis influenza vaccines unit will be combined with CSL's subsidiary, bioCSL.  Full Article

Exclusive: Express Scripts presses for expansion of drugs it won't cover

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

Search Stocks